Cipla (CIPLA) — Announcement

1 Announcement 🔴 High Importance ✨ Positive 📄 PDF

Cipla Limited has signed a marketing and distribution agreement with Eli Lilly to launch Yurpeak™, a second brand of Tirzepatide in India. Tirzepatide, a dual GIP/GLP-1 receptor agonist for type 2 diabetes and chronic weight management, was initially launched by Lilly as Mounjaro® in March 2025. Lilly will manufacture and supply the product at the same price, enabling Cipla to expand access beyond Lilly's established urban presence across India's underserved markets.

2 Announcement Neutral 📄 PDF

Cipla Limited intimated stock exchanges of a Non-Deal Roadshow scheduled for November 3-4, 2025 in the United States, organized by Citigroup Global Markets India Private Limited. Management will conduct one-on-one and group meetings with analysts and institutional investors. The schedule remains subject to change due to unforeseen circumstances. This is a routine investor engagement activity disclosed under SEBI Listing Regulations.

📊 Stock Analysis — CIPLA ✨ Ask AI About This

About Cipla Limited (CIPLA)

Healthcare · Pharmaceuticals & Biotechnology · Listed on NSE

Market Cap: ₹1,15,682.55 Cr P/E: 25.4 ROE: 14.6% ROCE: 19.4%

View full CIPLA stock details →

📡 Get AI alerts when CIPLA files next

Free • Daily 5 PM digest • Track filings, board meetings, and corporate actions

Track CIPLA — Free

💡 Ask AI about this filing

"How does this announcement affect Cipla Limited's outlook?" "What did Cipla Limited announce on 23 October 2025?" "Is this positive or negative for CIPLA?"

Ask AI Free →

📊 More CIPLA filings

See all CIPLA filings →

🔥 Also filed on 23 October 2025

AXISBANK Axis Bank Limited Corporate Action BAJFINANCE Bajaj Finance Limited Financial Results COLPAL Colgate Palmolive (India) Limited Financial Results COLPAL Colgate Palmolive (India) Limited Corporate Action COLPAL Colgate Palmolive (India) Limited Corporate Action TITAN Titan Company Limited Corporate Action

View all today's announcements →

Source: Stock Announcements. Analysis by StockFin.ai. For informational purposes only — not investment advice.

Editorial & Data Transparency Notice

This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.

📡 Get AI alerts when CIPLA files new disclosures

Track CIPLA filings, board meetings, and corporate actions. Free email alerts at 5 PM.